MaxCyte, Inc. (NASDAQ:MXCT) Position Increased by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC grew its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 66.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,230,182 shares of the company's stock after acquiring an additional 890,353 shares during the period. Chevy Chase Trust Holdings LLC owned about 2.10% of MaxCyte worth $6,088,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of MXCT. BNP Paribas Financial Markets acquired a new stake in shares of MaxCyte during the 4th quarter valued at approximately $56,000. Deutsche Bank AG increased its stake in MaxCyte by 65.0% during the fourth quarter. Deutsche Bank AG now owns 98,436 shares of the company's stock valued at $409,000 after purchasing an additional 38,782 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of MaxCyte by 51.4% during the fourth quarter. Hsbc Holdings PLC now owns 48,791 shares of the company's stock worth $199,000 after purchasing an additional 16,554 shares during the period. Two Sigma Advisers LP bought a new position in shares of MaxCyte in the 4th quarter worth about $74,000. Finally, Renaissance Technologies LLC lifted its position in shares of MaxCyte by 47.9% in the 4th quarter. Renaissance Technologies LLC now owns 281,200 shares of the company's stock worth $1,170,000 after buying an additional 91,100 shares during the last quarter. Institutional investors own 68.81% of the company's stock.

MaxCyte Trading Down 0.9%

MXCT stock traded down $0.02 during trading on Monday, hitting $2.18. The company had a trading volume of 444,799 shares, compared to its average volume of 616,813. The firm has a market capitalization of $232.00 million, a price-to-earnings ratio of -5.45 and a beta of 1.28. The business has a 50 day moving average of $2.37 and a 200 day moving average of $3.26. MaxCyte, Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $5.20.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $10.39 million during the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative return on equity of 19.90% and a negative net margin of 110.92%. As a group, equities analysts predict that MaxCyte, Inc. will post -0.42 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of MaxCyte from a "sell" rating to a "hold" rating in a research note on Sunday, June 8th. Stifel Nicolaus dropped their price target on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. Finally, BTIG Research set a $6.00 price objective on MaxCyte and gave the stock a "buy" rating in a research report on Wednesday, March 12th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.